Product Information

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB is a generic product labeled by Solco Healthcare US LLC, priced at $0.9013 per EA under NDC 43547046009. Its NADAC has been published 164 times since Jul 5, 2023.

FDA first approved this application on Apr 11, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB

candesartan cilexetil and hydrochlorothiazide
$0.9013per EA

Strength

32; 12.5 mg/1; mg/1

NDC

43547046009

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA207455

FDA Approved

4/11/2018

TE Code

AB

On Market Since

11/20/2017

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has been published 164 times since Jul 5, 2023, and over the history we have for it it has declined 47.5%. The table below summarizes its recorded NADAC range and movement.

Current price$0.9013 per EA
All-time high$1.7884 (Dec 13, 2023)
All-time low$0.7888 (Nov 20, 2024)
52-week high$1.2226
52-week low$0.9013
Median price$1.1725
Average price$1.2201
Largest weekly change-41.2% (Nov 20, 2024)
Weeks tracked164
Tracking sinceJul 5, 2023

Price History

1W

-9.5%

1M

-9.5%

3M

-23.8%

6M

-16.5%

1Y

-21.3%

3Y

-33.8%

5Y

N/A

All

-47.5%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB, manufactured by Solco Healthcare US LLC, is $0.9013 per EA (NDC 43547046009), effective Aug 19, 2026.

How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB changed over time?

Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has declined 47.5%. It has been tracked across 164 weekly CMS publications since Jul 5, 2023.

What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

Since Jul 5, 2023, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has ranged from a low of $0.7888 (Nov 20, 2024) to a high of $1.7884 (Dec 13, 2023), with a median of $1.1725 per EA.

Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB in a comparable dosage form, but none are currently priced below it.

Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB (NDC 43547046009) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.